Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Sumitomo Mitsui Trust Group Inc. decreased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 4.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 755,970 shares of the company’s stock after selling 33,252 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.99% of Nurix Therapeutics worth $8,981,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Nurix Therapeutics by 1,711.9% during the 4th quarter. FMR LLC now owns 10,634,231 shares of the company’s stock valued at $200,349,000 after purchasing an additional 10,047,329 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at $25,120,000. Soleus Capital Management L.P. grew its holdings in shares of Nurix Therapeutics by 97.3% during the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock valued at $39,617,000 after purchasing an additional 1,036,999 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at $16,447,000. Finally, Boxer Capital Management LLC bought a new position in shares of Nurix Therapeutics during the 4th quarter valued at $10,608,000.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $12.73 on Friday. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The company’s 50-day simple moving average is $11.10 and its 200 day simple moving average is $14.16. The firm has a market capitalization of $970.54 million, a P/E ratio of -4.55 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The business had revenue of $18.45 million for the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the previous year, the firm posted ($0.76) earnings per share. On average, equities research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Houte Hans Van sold 6,198 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares of the company’s stock, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gwenn Hansen sold 3,377 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider directly owned 61,516 shares in the company, valued at $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock worth $137,096 in the last three months. 7.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NRIX. Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 21st. Stifel Nicolaus cut their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Wells Fargo & Company cut their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.18.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.